Recently, Boshuizen al. 2021 showed that targeting immunotherapy-resistant melanoma and lung cancer using an AXL-targeting ADC enhances the sensitivity to immune checkpoint inhibitors (IC) [142]. Here, AXL is linked to lung carcinoma.